Superhuman

Superhuman CEO: The Strategy to Turn Standalone Apps Into a $13 Billion Suite

Aug 20, 2026 · 1:07:27

Shishir Mehrotra, CEO of Superhuman—now bundling Superhuman Mail, Grammarly, Coda (as Superhuman Docs), and Superhuman Go—explains how he built a $13 billion suite by overturning conventional wisdom on bundling. He describes meeting Rahul Vora at a Hawaii conference, rebranding 16-year-old Grammarly under the Superhuman name, and lessons from Reid Hoffman about people-first, long-term building. On the 'SaaS apocalypse,' he argues AI agents are new teammates that increase the need for coordination tools like CRMs, while pricing shifts from per-seat to usage because virtual employees don't fill out W-2s. He details his inbox-zero system using Superhuman Mail's 'splits,' and advises founders to build boards as 'weird teams' with soft connection and non-jeopardy feedback.

Why We Sold To Grammarly | Rahul Vohra

Jun 21, 2026 · 1:01:18

Rahul Vohra, founder of Superhuman and now CEO of Superhuman Group after the company's acquisition by Grammarly, argues that email remains the most enduring layer of work identity and that AI will radically transform the inbox experience while distribution and taste-driven focus are the lasting moats in an era of near-zero software costs. He explains that email addresses are owned by companies and serve as the root identity and authentication unit, with professionals spending 3 billion hours daily on email. Voice features like Right With Voice on mobile now drive 30% of usage gains, and the 'Sent via Superhuman' signature still generates 20% of site traffic. The acquisition story reveals that Grammarly independently chose the Superhuman name via a branding agency, leading to the rare rebrand of the acquirer. Superhuman Group operates as a multi-product bundle ($15/$30 per month) spanning email, documents (Coder), writing agents (Grammarly), and proactive AI (Superhuman Go), with priorities on M&A to fill missing categories like chat. Vohra also angel-invests via Todd and Rahul Capital, backing companies like Loyal (which received FDA efficacy approval for a dog lifespan drug) and…